Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Wenping Lin et al.|Journal of Clinical Oncology|2021Cited by 30
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapyMin Deng, Rong Guo, Wei Wei et al.|Annals of Medicine|2022Cited by 22
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinomaRongce Zhao, Rongping Guo, Jing Zhou et al.|Frontiers in Immunology|2024Cited by 17
Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.Wei Wei, Rongping Guo, Shaohua Li et al.|Journal of Clinical Oncology|2023Cited by 13
Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinomaMin Deng, Rong-Ping Guo, Jiabao Lin et al.|BMC Cancer|2021Cited by 6